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Prothrombin is activated to thrombin by the prothrombinase complex through sequential cleavage at
two distinct sites. This occurs at sites of vascular injury in a highly regulated cascade of serine protease
and cofactor activation, where activated platelets provide a suitable surface for protease/cofactor/sub-
strate assembly. The precise structural and conformational changes undergone during the transition
from prothrombin to thrombin have been studied for decades, and several structures of prothrombin
fragments along the activation pathway have been solved. Here we present a new structure analyzed in
context of other recent structures and biochemical studies. What emerges is an unexpected mechanism
that involves a change in the mode of binding of the F2 domain (fragment 2) on the catalytic domain
after cleavage at Arg320, and a subsequent reorientation of the linker between the F2 and catalytic
domain to present the Arg271 site for cleavage.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
A critical event in hemostasis is the conversion of prothrombin
from an inactive zymogen to the active enzyme thrombin. This is
the end-point of the blood coagulation cascade and is regulated by
many factors [1,2]. Once formed, thrombin uses two anion-binding
exosites (I and II) and its active site to recognize several substrates
(Fig. 1) [3,4]. Maintenance of prothrombin as a zymogen requires
the encryption of these three sites to prevent premature in-
teractions. Catalytic inactivity is a general feature of zymogens of
serine proteases, but encryption of the two exosites is equally
important in prothrombin to prevent the dysregulation of hemo-
stasis. If exosite I were ‘competent’ then prothrombin could satu-
rate thrombomodulin on the vascular endothelium, thereby
precluding binding by active thrombin and preventing protein C
activation. It could also bind to ﬁbrinogen and potentially block
ﬁbrin formation, and similarly bind to circulating fV and fVIII
thereby preventing their activation [5e9]. Exosite II exposure
would localize prothrombin to the intact vascular surface via
heparan sulfate binding and to platelets via GpIba binding [10e13].
Most serine protease zymogens are converted to active).
B.V. This is an open access article uproteases through the cleavage of a single scissile bond between
residues 15 and 16 (chymotrypsin numbering). The structural
rearrangements that lead to the development of a functional active
site cleft is well understood, and involves the ‘insertion’ of the new
N-terminus (normally Ile16) into the so-called ‘activation pocket’
[14,15]. However, it can also be effected in the absence of cleavage
by peptides and certain virulence factors such as staphylocoagulase
[16e18]. This results in the formation of the principal substrate-
binding pocket (S1) and the oxyanion hole. Prothrombin is an un-
usual zymogen in the sense that cleavage of the Arg15-Ile16
(Arg320-Ile321 in prothrombin numbering) peptide bond does not
result in a fully functional enzyme, but in the disulﬁde-linked
enzyme intermediate meizothrombin (mIIa) [19]. Complete acti-
vation to thrombin requires an additional cleavage at residue
Arg271 (prothrombin numbering) to release the catalytic domain
from the N-terminal fragment 1.2 (F1.2), composed of the Gla
domain and two kringle domains (Fig. 2). Two potential pathways
for prothrombin activation are available depending on which of
these two cleavage events occurs ﬁrst. With factor Xa alone,
cleavage at Arg271 is kinetically favored, and cleavage at Arg320
progressing relatively slowly. Initial cleavage at Arg271 results in
formation of the zymogen precursor prethrombin-2 (pre2) and F1.2
[20]. In the presence of factor Va and phospholipid membranes,
prothrombinase cleaves ﬁrst at the Arg320 site, followed by
cleavage at Arg271 [21,22]. The ordered cleavage of Arg320nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Structural features of thrombin. Surface representation of thrombin in gray in
the standard orientation showing the positions of exosite I (in blue), exosite II (in red),
the activation domain (in green), and the active site cleft.
T.E. Adams, J.A. Huntington / Biochimie 122 (2016) 235e242236followed by Arg271 of prothrombin by prothrombinase has been
referred to as ‘ratcheting’ because the zymogen to protease
conformational change seems to present the second cleavage site to
the active site of fXa [23]. A recent study concluded that cleavage byFig. 2. Prothrombin activation pathways. The proteolytic conversion of the zymogen pro
Arg320. In the presence of factor Xa alone, initial cleavage at Arg271 produces F1.2 and pr
presence of factor Va and phospholipids, factor Xa cleaves Arg320 producing the active interm
F1.2 (right pathway). The Gla domain (GLA), kringle 1 (K1), kringle 2 (K2), and protease doprothrombinase through the meizothrombin intermediate may be
attributed to the use of synthetic phospholipids and that activation
of prothrombin on platelets proceeds via the pre2 intermediate
[24]. However, it is clear that the meizothrombin pathway pre-
dominates provided prothrombin is anchored to the same surface
as the prothrombinase complex [25], and this must thus be
considered the physiological pathway, in spite of the use of syn-
thetic phospholipid vesicles.
Exosite I exists in a ﬂexible, low-afﬁnity state in prothrombin
that is ordered upon conversion to thrombin [26]. Exosite II is
occupied in prothrombin by the second kringle domain, fragment
2 (F2), blocking exosite II mediated interactions, and effectively
encrypting this exosite in prothrombin. F2 binds 2-fold more
weakly to thrombin than to the zymogen pre2, and F1.2 binds to
thrombin 20-fold more weakly than to pre2 [27]. This suggests
that formation of meizothrombin through cleavage at Arg320 may
help release the catalytic domain from its interaction with F2. It is
unclear how the covalent linkage of the F1 domain affects the
binding of F2 to the catalytic domain, but a direct interaction
between the F1 and F2 domains is unlikely. The conformational
changes in the zymogen activation domain upon cleavage at
Arg320 matures exosite I, although meizothrombin is still some-
what deﬁcient in its ability to bind to exosite I-dependent ligands
[28]. Thus, cleavage at both Arg320 bond and removal of F1.2 by
cleavage at Arg271 is required for the formation of fully competent
exosites on thrombin. Here we present a new structure of the
pre2/F2 complex in context of other structures of prothrombin
fragments containing at least the F2 and catalytic domains, and
investigate how conformational change might contribute to pro-
thrombin activation.thrombin to the enzyme thrombin is the result of proteolytic cleavage at Arg271 and
e2 (left pathway), followed by cleavage at Arg320 generating active thrombin. In the
ediate meizothrombin, which is further processed at Arg271 to release thrombin from
mains (Pro) are shown as ovals showing linkers between each as lines.
Table 1
Data processing and reﬁnement statistics for 3K65.
Crystal
Space group P41212
Cell dimensions (Å) a ¼ b ¼ 73.53 c ¼ 205.88
a ¼ b ¼ g ¼ 90
Solvent content (%) 62.4
Data Processing
Wavelength (Å) 0.97 (Diamond I04)
Resolution (Å) 51.50e1.85 1.95e1.85
Total reﬂections 369318 54430
Unique reﬂections 48719 7012
Multiplicity 7.6 7.8
<I/s(I)> 16.5 3.7
Completeness (%) 99.0 99.5
Rmerge 9.1 37.4
Model Details
# of atoms:
Protein 2779
Water 231
Average B-factor (Å2) 36.4
Reﬁnement Statistics 12.00e1.85 1.90e1.85
Reﬂections (working/free) 46006/2463 3286/173
Rfactor/Rfree (%) 20.8/23.3 32.8/31.5
r.m.s. deviation from ideality bonds (Å)/Angles () 0.028/2.19
Ramachandran plot (%)
Most favored 95.6
Additionally allowed 4.4
Outliers 0.0
T.E. Adams, J.A. Huntington / Biochimie 122 (2016) 235e242 2372. Materials and methods
2.1. Protein expression and puriﬁcation
Human prethrombin-2 was expressed in E. Coli using our pre-
viously described method [29]. Brieﬂy, wild-type human
prethrombin-2 in the pET23(þ) vector (Novagen) was converted to
the S195A (chymotrypsin numbering) variant using site directed
mutagenesis and transformed into the BL21 STAR (DE3) pLysS
E. Coli strain (Invitrogen). The protein was expressed into inclusion
bodies, washed, and then solubilized in 1 mL 0.1% tri-ﬂuoroacetic
acid. The solubilized protein was diluted to 10 mL with the addi-
tion of 9 mL of 7 M guanidine hydrochloride and 30 mM L-cysteine,
and refolded by drop-wise addition of 2.5 L of 50 mM TriseHCl,
pH7.4, 0.6M L-arginine, 500mMNaCl,1mMEDTA,1mM L-cysteine,
10% glycerol, 0.2% Brij-58. The protein was then loaded onto a 5 mL
HiTrap heparin Sepharose column (GE Healthcare) and eluted with
a 0.25e1 M NaCl gradient over 5 column volumes. Fractions con-
taining prethrombin-2 were pooled and dialyzed into 20 mM Tris,
100 mM NaCl, pH7.4.
2.2. Digestion of human plasma prothrombin and puriﬁcation of
fragment-2
Human plasma prothrombin was puriﬁed as previously
described [30]. Prothrombin was digested with 0.5 U recombinant
factor Xa per mg prothrombin (Novagen) in 10 mM Tris, 100 mM
NaCl, 1 mM CaCl2 overnight at 22 C. The cleavage products were
initially separated using a 5 mL HiTrap heparin Sepharose column
where both factor Xa and prethrombin-2 were retained, while
fragments 1, 2, and prothrombin were collected in the ﬂow-
through. Following 3-fold dilution with 20 mM Tris, pH8.0, the
ﬂow-through containing fragments 1 and 2 were loaded onto a
5 mL HiTrap Q Sepharose column and separated with a gradient
elution from 0 to 0.6 M NaCl over 10 column volumes. Fractions
containing fragment 2 were pooled, concentrated, and dialyzed
against 20 mM Tris, pH7.4.
2.3. Crystallization of hF2-preII(S195A) complex
Recombinant prethrombin-2 was combined with a 20% molar
excess of plasma derived fragment 2 and concentrated to 8.7 mg/
mL. Initial crystallization trials were setup using 200 nL drops on a
Screenmaker 96 þ 8 Xtal crystallization robot (Innovadyne).
Several preliminary crystals were observed after 1e2 days from the
Morpheus Screen (Molecular Dimensions). Following optimization,
large crystals (200  200  300 mm) grew in 1e3 days in 10% Al-
cohols mix, 10% Buffer 1 Mix, 40% EDO_P8K Mix of the Morpheus
Screen.
2.4. Data collection, processing, and reﬁnement
Data from a single ﬂash-cooled crystal were collected at Dia-
mond beamline I04 (Didcot, UK) and indexed using Mosﬂm [31].
The data were processed with the CCP4 program suite using Scala
and Truncate [32] followed by molecular replacement using Phaser
[33]. Initial reﬁnement was carried out iteratively with successive
rounds of model building followed by simulated annealing using
CNS [34]. XtalView [35] was used for model building. Data pro-
cessing and reﬁnement statistics are given in Table 1. Figures were
made using Pymol [36], and the interaction area was calculated
using AREAIMOL (part of the CCP4 suite). Coordinates and structure
factors are deposited in the Protein Data Bank under PDBID code
3K65.3. Structural comparison
A comparison of all the structures of prothrombin and frag-
ments, both zymogen and enzyme, show several important struc-
tural rearrangements that the protein undergoes during activation
[37e42] (Fig. 3). Early structures of the human PPACK-thrombin/F2
complex (PDBID:2HPQ) and bovine PPACK-meizothrombin(desF1)
(PDBID:1A0H) show similar binding interfaces for F2 on the cata-
lytic domain, which we have termed ‘mode 1’ (red (in the web
version) in Fig. 4). The subsequent structure of human PPACK-
meizothrombin(desF1) (PDBID:3E6P) conﬁrmed this binding
interface [43]. In all of these structures the catalytic domain has
been activated by cleavage at Arg320 and the active site of the
enzyme was covalently bound to the inhibitor PPACK (D-phenyl-
alanyl-prolyl-arginyl chloromethylketone). An extensive contact
surface between F2 and the catalytic domain is observed in these
structures, burying a total of ~1600 Å2 (Fig. 5), involving several
salt-bridges, hydrogen bonds, and hydrophobic contacts (Fig. 6).
The interface interposes the basic exosite II of catalytic domainwith
the highly acidic face of F2. Important ionic interactions include:
Asp223 and Asp225 with Arg409 (93 in chymotrypsin numbering)
and Arg418(101); Glu226 with Arg490(165); Glu227 with
Arg500(175); and Asp239 with Arg413(97). Other basic residues on
the C-terminus, Arg565(233), Lys568(236) and Lys572(240), do not
form salt-bridges, although they have been shown to be critical for
binding other exosite II ligands. In terms of number and types of
contacts, the most important residue in exosite II is Arg409(93). It
participates in multiple salt-bridges, water-mediated hydrogen
bonds, pi-stacking and hydrophobic interactions, and accounts for
up to 18% of the buried surface area.
The more recent structures of human prethrombin 1
(PDBID:3NXP), human prothrombin(desGla) (PDBID:4HZH), and
human prothrombin(D146e167) (PDBID:4NZQ) show an alternate
binding mode for F2 on the catalytic domain [37,38,42]. This new
binding mode (mode 2) shows a large shift in position, with a
rotation of approximately 30 accompanied by a translation of ~6 Å
relative to the mode 1 structures (Fig. 4). Mode 2 is slightly more
Fig. 3. Structures of prothrombin and activation fragments. Cartoon ribbon representations of all prothrombin and fragment structures containing the protease domain bound to
the F2 domain, oriented with the active site located at the lower right. The corresponding protein data bank identiﬁcation code (PDBID) is displayed below the structure name in
parentheses.
T.E. Adams, J.A. Huntington / Biochimie 122 (2016) 235e242238intimate, with a buried surface area of ~1800 Å2 (Fig. 5). As before,
the interface between the F2 and catalytic domain is composed
primarily of complimentary ionic interactions (Fig. 6). However, in
the mode 2 structures Asp223 and Asp225, which form salt-bridges
to Arg409(93) and Arg418(101) in mode 1, now form salt-bridges to
Lys572(240) and Lys568(236), and Arg409(93) and Arg418(101)nowmake contacts with Glu226 and Glu227. Additional differences
from binding mode 1 include hydrogen bonding interactions
Glu249 with Arg490(165) and Lys494(169), Glu254 with
Arg443(126), and Glu255 with Arg443(126).
This suggests that the binding mode of F2 is determined by the
conformation of the catalytic domain. In binding mode 1 the
Fig. 4. Binding modes of fragment-2. Alignment of all structures containing the F2 domain reveal two overlapping binding sites on the protease domain. Stereo view of the
protease domain of prethrombin-1 (PDBID:3NXP) is shown as gray surface representation. Fragment 2 in the thrombin/F2 complex (PDBID:2HPQ), pre2/F2 complex (PDBID:3K65),
and meizothrombin(desF1) (PDBID:1A0H,3E6P) bind via ‘mode 1’, shown as red cartoon. Fragment 2 in prothrombin (PDBID:4HZH,4NZQ) and prethrombin-1 (PDBID:3NXP)
structures binds via ‘mode 2’, shown in green cartoon.
Fig. 5. Footprint of fragment-2 on the protease domain in mode 1 and 2 structures. Surface representation of various prothrombin/fragment structures showing surfaces within
the protease domain that interact with F2. Thrombin is shown in blue; prethrombin-2 is shown in pink; meizothrombin is shown in cyan; prethrombin-1 is shown in magenta;
prothrombin from 4NZQ is shown in gray, and from 4HZH is shown in orange. Residues within 3.5 Å of F2 in each structure have been colored yellow with important basic residues
of the catalytic domain labeled.
T.E. Adams, J.A. Huntington / Biochimie 122 (2016) 235e242 239catalytic domain is cleaved at Arg320 and locked in its enzyme state
through active site inhibition, whereas in binding mode 2, the
catalytic domain is still in its zymogen state with an intact Arg320-
Ile321 bond. To investigate the role of the conformation of thecatalytic domain in the F2 binding mode, we determined a 1.85 Å
structure of pre2 in complex with F2 (Table 1). It shows that, even
though pre2 is still a zymogen, F2 binds to the catalytic domain
using mode 1. The structure also reveals increased disorder within
Fig. 6. Interaction diagram of modes 1 and 2. The interactions between the second kringle domain (F2) and the protease domain (Pro) are shown for the enzyme-like mode 1 and
the zymogen-like mode 2. The schematic illustrates that conservation of interactions within modes. Three structures for each mode are represented (Mode 1: 2HPQ solid black lines,
3E6P dashed black lines, 3K65 dotted black lines; Mode 2: 4NZQ solid black lines, 4HZH dashed black lines, 3NXP dotted black lines).
T.E. Adams, J.A. Huntington / Biochimie 122 (2016) 235e242240the zymogen activation domain when compared to that of pre2
alone. It appears that cleavage of either Arg271 or Arg320 leads to
transition from binding mode 2 to 1.
4. Linker between F2 and protease domains
Cleavage at Arg320 causes a shift from mode 2 to mode 1, but it
might also result in a rearrangement of the linker containing
Arg271 between the F2 and protease domain. The crystal structure
of bovine meizothrombin(desF1) (PDBID:1A0H) shows the linker
between the 120- and C-terminal helices on the catalytic domain
(Fig. 7). This is the only structure displaying electron density for this
region. In structures with binding mode 2 the F2 domain occupies
the cleft formed by the two helices that bind this linker in meizo-
thrombin. The transition to binding mode 1 shifts the F2 domain
away from these helices allowing the linker containing Arg271 to
dock. It is possible that this apparent reorientation of the linker
between F2 and the catalytic domain is part of the ‘ratcheting’
mechanism of prothrombin activation.Fig. 7. Conformational rearrangement of the linker after Arg320 cleavage. The linker bet
shown as yellow cartoon. Arg271 is shown yellow sticks. The protease domain is displayed as
F2 binding in prethrombin-1 is shown as green cartoon (mode 2). The F2 domain bound in5. The environment of Arg320
Recent structural studies by the Di Cera group have suggested
that part of the mechanism of accelerated cleavage of Arg320 by
assembled prothrombinase is the ‘exposure’ of the activation loop
containing the Arg320-Ile321 bond [39,44]. This is based on the
observation in a crystal structure (3SQE) of a ‘buried’ Arg320 side
chain, due to interactions with nearby negatively charged residues,
Glu311, Asp318 and Glu323. The authors failed to mention the
extensive crystal contact with a symmetry-related molecule in this
area intimately involving the side chains of Tyr316, Asp318 and
Arg320, and the lack of electron density for the side chain of Glu323
(Indeed, there is strong negative difference density corresponding
to where it is placed.). The relevance of the trapping of Arg320 in
this ‘anionic cage’ was studied by mutating the three acidic resi-
dues, Glu311, Asp318 and Glu323, to alanine. The result was pro-
thrombin capable of autoactivation to thrombin over long
incubation periods. The authors concluded that this was evidence
of improved ﬂexibility of the Arg320-Ile321 bond due to theween the F2 domain and the protease domain of bovine meizothrombin (PDB:1A0H) is
a surface representation and the F2 domain is displayed in red as cartoon (mode 1). The
mode 1 sterically blocks the linker of in the zymogen conformation (mode 2).
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consider the more likely explanation that substitution of acidic
residues ﬂanking the scissile bond will have a profound inﬂuence
on the ability of thrombin to recognize a substrate. Indeed, several
reports have concluded that acidic residues at either the P3 or P30
positions (corresponding to Asp318 and Glu323 in prothrombin)
antagonize cleavage by thrombin, and that hydrophobic or basic
residues are favored [45e49]. Thus, altering the activation loop
from IDGR-IVE to IAGR-IVA might have an effect on the structure of
the region, but it will certainly impact thrombin's ability to cleave
it. The argument that it is the sequence that matters, not ﬂexibility,
is strengthened by insensitivity of mutation solely at Glu311 that
would be predicted to have the most profound effect on the
orientation and burying of Arg320 [44]. It would be interesting to
know if the neutralizing mutations in the activation loop of pro-
thrombin alters its ability to be cleaved by fXa, alone or in the
presence of fVa and membranes, or indeed by other proteases, such
as ecarin. The accessibility of the activation loop of prothrombin
might be improved upon fVa binding, but it is more likely that it is
simply presented to the active site of fXa in the context of the
assembled prothrombinase complex.
6. F2 in ratcheting
The exact mechanism of prothrombin activation by pro-
thrombinase, in particular how a single enzyme complex can be
responsible for two sequential cleavage events at sites separated
>30 Å, has been the matter of some debate over the last 30 years.
Some reports have suggested two different interconverting forms
of prothrombinase exist, one cleaving at Arg320 and another at
Arg271 [50,51]. However, the overwhelming weight of experi-
mental evidence supports a single enzyme complex that cleaves
prothrombin at Arg320 to meizothrombin, and that it is the change
in conformation of the substrate that presents the second Arg271
site. A recombinant prothrombin variant in which the sequence
immediately following the Arg320 cleavage site was replaced with
residues that do not allow transition to an active protease showed
normal cleavage at Arg320 by prothrombinase, but subsequent
cleavage at Arg271 was impaired [23], resulting in a build-up of
meizothrombin. The conclusion is that presentation of the Arg271
cleavage site requires the conversion of the catalytic domain to its
active enzyme conformation. To test this, bacterial staph-
ylocoagulase was used to conformationally activate the catalytic
domain without cleavage at Arg320. The covalent inhibitor PPACK
was then used to lock the catalytic domain in an activated confor-
mation, followed by removal of staphylocoagulase. This pro-
thrombin species showed accelerated cleavage at Arg271 and
inhibition of cleavage at Arg320. We now see that the transition
from the zymogen to enzyme conformation in the catalytic domain
also leads to the reorientation of the F2 domain and possibly the
linker between the F2 and catalytic domains. These conformational
changes may be important for positioning the Arg271 site for efﬁ-
cient cleavage, thus constituting part of the molecular basis of
prothrombin processing.
Data deposition
Coordinates and structure factors are deposited in the Protein
Data Bank under PDBID code 3K65.
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